Skip to main content

Platform

One protected intelligence core. Four governed environments.

Decidian Intelligence is a governed venture-development control plane that converts a medical invention into an evidence-backed sequence of clinical, scientific, intellectual-property, regulatory, engineering, manufacturing, commercial, and capital decisions.

Product definition

Protected intelligence core

Twelve mechanisms behind every Decidian decision

All four environments read from and write to one protected core. These are the mechanisms that make a conclusion explainable, revisable, and attributable to a named approver.

01

Secure intake and normalized project record

Operating capability

Everything you submit becomes one structured project file.

Files are scanned, sandboxed during parsing, hashed, and receipted, then extracted once into a normalized record of product identity, intended use, population, users, mechanism, jurisdiction, stage, and decision sought. High-impact facts are confirmed by your team before anything depends on them.

02

MedTech ontology

Operating capability

A shared vocabulary so terms mean the same thing everywhere.

Products, claims, indications, populations, pathways, standards, processes, evidence types, and partner capabilities are represented in one controlled model, so a claim written in an intake form and a claim cited in a regulatory scenario refer to the same object.

03

Evidence and provenance graph

Operating capability

Every claim points back to the exact source that produced it.

Extracted facts, cited literature, standards, precedents, and internal data are stored as linked nodes carrying authority, directness, integrity, independence, recency, and applicability, with the source span retained for inspection.

04

Retrieval-augmented intelligence

Operating capability

Analysis is grounded in retrieved sources, not model recall.

Analysis draws on retrieved project and reference material under an explicit source policy. Statements that cannot be grounded in a retrievable source are not produced as conclusions.

05

Specialized agent orchestration

Operating capability

Narrow software roles, each with strict limits.

Each agent is a bounded role with a source policy, tool budget, output schema, confidence method, prohibited actions, and escalation path. Agents produce proposals; they never hold authority.

06

Hypercube multidimensional reasoning

Operating capability

Project state is addressable by domain, jurisdiction, stage, and scenario.

State is held as addressable cells across project, domain, jurisdiction, stage, scenario, evidence state, and version, so a regulatory conclusion in one jurisdiction never silently overwrites another.

07

Versioned policy packs

Operating capability

The rules applied to your project are pinned and dated.

Classification logic, evidence thresholds, gate criteria, and disclosure rules are versioned artifacts. A decision records the policy version that produced it, so a later rule change is visible as a change rather than a silent rewrite.

08

Contradiction detection

Operating capability

Conflicts between your own documents are surfaced, not averaged.

Conflicting intended-use statements, incompatible claims, and disagreeing sources are raised as explicit contradictions attached to the affected decisions, and they block confident conclusions until resolved.

09

Confidence and uncertainty

Operating capability

Ranges and assumptions instead of false precision.

Conclusions carry a confidence method and an uncertainty statement; cost and schedule are expressed as P50 and P80 ranges with assumptions and sensitivity drivers, and numeric readiness is suppressed when evidence completeness is too low to be meaningful.

10

Decision ledger

Operating capability

An append-only record of what was decided and why.

Every decision object records alternatives, evidence, contradictions, assumptions, confidence, safety and regulatory implications, approver, review date, cost and timeline range, next action, and eventually the observed outcome.

11

Human authorization

Operating capability

People sign; software proposes.

Binding conclusions route to reviewers with the required authority. Approval, conditions, dissent, override rationale, escalation, and signature are first-class records, and unauthorized state transitions fail closed.

Honest labelling

Operating capability versus unvalidated future claim

Capabilities above are labelled by status. Anything describing measured accuracy, savings, speed, or success rates is a pilot measurement target and is presented as a planning assumption until controlled measurement is complete.

Planned, not yet delivered

Outcome capture and model calibration

Realized costs, timelines, submission results, and study outcomes are captured and compared with prior forecasts, and calibration is tracked by product type and stage. Calibration quality improves only as real outcomes accumulate.

Claims we will not make yet

  • No accuracy, speed, cost-saving, or success-rate figure is published as an achieved result.
  • Calibration performance depends on accumulated outcomes and cannot be claimed in advance.
  • Coverage beyond U.S. devices and software as a medical device is planned scope, not delivered scope.
  • Pricing figures in planning material are hypotheses, not validated prices.

Architecture

Intelligence, governance, and execution stay separate

Decidian automates the first layer, controls the second, and orchestrates rather than pretends to replace the third.

Intelligence

Retrieval, classification, analysis, simulation, matching, and monitoring.

Governance

Provenance, permissions, policy, human approvals, electronic signatures, decision history, and deterministic replay.

Execution

External experts, laboratories, CROs, engineering firms, manufacturers, regulatory representatives, and authorized intermediaries.

Commercialization blueprint

A stage-gated roadmap where each step carries its decision state, capital range, partner dependency, and the steps it would invalidate if it changed.

Regulatory strategy

Fix the pathway and the evidence burden it imposes.

Capital effect
P50 USD 240k · P80 USD 400k
Partner dependency
Notified-body advisor
Depends on
Intended use, Verification and validation
Invalidates if changed
Evidence generation, Reimbursement
Text equivalent
  1. Intended useCONDITIONAL GO. Fix the population, setting, and claim wording every later decision inherits. Capital: Not capital-bearing. Partner: Clinical advisor. Depends on: nothing upstream.
  2. Design inputsGO. Convert intended use into verifiable requirements under design control. Capital: P50 USD 180k · P80 USD 260k. Partner: Design consultancy. Depends on: intended-use.
  3. PrototypeGO. Demonstrate feasibility against the stated design inputs. Capital: P50 USD 420k · P80 USD 640k. Partner: Prototype shop. Depends on: design-inputs.
  4. Verification and validationHOLD. Prove the device meets its inputs and its intended use in real conditions. Capital: P50 USD 900k · P80 USD 1.5M. Partner: Test lab. Depends on: prototype, design-inputs.
  5. Regulatory strategyCONDITIONAL GO. Fix the pathway and the evidence burden it imposes. Capital: P50 USD 240k · P80 USD 400k. Partner: Notified-body advisor. Depends on: intended-use, vv.
  6. Evidence generationHOLD. Generate the clinical and performance evidence the pathway requires. Capital: P50 USD 2.1M · P80 USD 3.8M. Partner: CRO. Depends on: regulatory.
  7. ManufacturingHOLD. Qualify processes, suppliers, and scale-up under quality control. Capital: P50 USD 1.4M · P80 USD 2.6M. Partner: CDMO. Depends on: vv.
  8. ReimbursementABSTAIN. Evidence a payment route in the intended setting of care. Capital: Range suppressed — evidence below threshold. Partner: Market-access advisor. Depends on: evidence, regulatory.
  9. CommercializationHOLD. Channel, pricing, and adoption plan consistent with the approved claim. Capital: P50 USD 1.1M · P80 USD 2.0M. Partner: Channel partner. Depends on: reimbursement, manufacturing.

Investor-match explanation

Matching is a diligence result, not a directory listing. Every criterion behind an inclusion or exclusion is shown, including founder permission, which can withhold a project outright.

Project Meridian — implantable sensing

Shown to investor

Every eligibility and mandate criterion is met or explicitly conditional, and the founder has granted scoped disclosure. The listing shows the conditions rather than hiding them.

  • EligibilityMet

    Required: Verified professional investor

    Actual: Verification current, expires in 214 days

  • Mandate compatibilityMet

    Required: Class II devices, clinical-stage

    Actual: Class II, clinical-stage

  • StageMet

    Required: Post-prototype, pre-submission

    Actual: Design verification underway

  • ModalityMet

    Required: Implantable or wearable sensing

    Actual: Implantable sensing

  • IndicationMet

    Required: Cardiometabolic

    Actual: Heart-failure monitoring

  • GeographyPartially met

    Required: US and EU

    Actual: US first, EU planned

  • Check sizeMet

    Required: USD 3–8M

    Actual: Round target USD 6M

  • Regulatory tolerancePartially met

    Required: Accepts De Novo risk

    Actual: Pathway contested; narrowing required

  • Evidence requirementsPartially met

    Required: Independent bench and field data

    Actual: Bench independent, field re-test pending

  • Strategic fitMet

    Required: Hospital channel synergy

    Actual: Two portfolio companies share the channel

  • ConflictsMet

    Required: No competing portfolio holding

    Actual: No conflict detected

  • Founder permissionMet

    Required: Explicit scoped grant

    Actual: Granted for readiness vector and gate history

Text equivalent
  • Project Meridian — implantable sensingShown to investor: Every eligibility and mandate criterion is met or explicitly conditional, and the founder has granted scoped disclosure. The listing shows the conditions rather than hiding them. Eligibility: required Verified professional investor, actual Verification current, expires in 214 days (Met). Mandate compatibility: required Class II devices, clinical-stage, actual Class II, clinical-stage (Met). Stage: required Post-prototype, pre-submission, actual Design verification underway (Met). Modality: required Implantable or wearable sensing, actual Implantable sensing (Met). Indication: required Cardiometabolic, actual Heart-failure monitoring (Met). Geography: required US and EU, actual US first, EU planned (Partially met). Check size: required USD 3–8M, actual Round target USD 6M (Met). Regulatory tolerance: required Accepts De Novo risk, actual Pathway contested; narrowing required (Partially met). Evidence requirements: required Independent bench and field data, actual Bench independent, field re-test pending (Partially met). Strategic fit: required Hospital channel synergy, actual Two portfolio companies share the channel (Met). Conflicts: required No competing portfolio holding, actual No conflict detected (Met). Founder permission: required Explicit scoped grant, actual Granted for readiness vector and gate history (Met).
  • Project Kelvin — surgical roboticsExcluded: Excluded for two independent reasons, either of which alone is sufficient. The exclusion reason is shown so the investor is not left guessing what the system is withholding. Eligibility: required Verified professional investor, actual Verification current (Met). Mandate compatibility: required Class II devices, actual Class III device (Not met). Stage: required Post-prototype, actual Post-prototype (Met). Modality: required Sensing, actual Robotic manipulation (Not met). Indication: required Cardiometabolic, actual General surgery (Not met). Geography: required US and EU, actual EU only (Partially met). Check size: required USD 3–8M, actual Round target USD 22M (Not met). Regulatory tolerance: required Accepts De Novo risk, actual PMA route (Not met). Evidence requirements: required Independent data, actual Internal only (Partially met). Strategic fit: required Hospital channel synergy, actual Adjacent channel (Partially met). Conflicts: required No competing holding, actual Competing portfolio holding identified (Not met). Founder permission: required Explicit scoped grant, actual No grant issued (Blocked).

Differentiation

Ten structural design choices

One ingestion, many decisions

Documents are normalized once and reused across the lifecycle.

Readiness vector, not an opaque score

Domain readiness stays visible instead of collapsing into a single number.

Uncertainty is a product feature

Every forecast carries distributions, assumptions, and sensitivity drivers.

ABSTAIN is enforceable

The system refuses to produce conclusions the evidence cannot support.

Highest-value next experiment

HOLD and PIVOT states identify the experiment most likely to change the decision per dollar and unit time.

Continuous diligence

New evidence triggers re-evaluation instead of a new static report.

Human authorization is native

Review, dissent, override, signature, and reason are first-class records.

Matching follows diligence

The exchange begins with qualified evidence, not a directory listing.

Outcome calibration

Forecasts are scored against reality and recalibrated by product type and stage.

Permissioned learning

Cross-project learning occurs only with consent, contractual authority, and de-identification.

Agents

What an agent is here

An agent is a bounded software role with an explicit source policy, tool budget, output schema, confidence method, prohibited actions, and escalation path. Agents never receive unrestricted access by default, and every agent output is a proposal until a human with the required authority acts on it.

Work the platform removes

  • Repeated manual extraction from the same source documents
  • Untraceable claims copied between decks and reports
  • Late discovery of classification, reimbursement, IP, safety, or manufacturing blockers
  • Deterministic budgets that hide uncertainty and correlated delays
  • Screening based primarily on narrative quality
  • Vendor selection before requirements are understood
  • Static diligence that becomes obsolete after a milestone or regulatory change

See the control plane against a real project record

Demonstrations show evidence lineage, gate logic, and the exact conditions under which the system abstains.

Request a demonstration